Clinical Outcomes of Biologic Mesh: Where Do We Stand?

被引:14
|
作者
Harris, Hobart W. [1 ]
机构
[1] UCSF, Dept Surg, San Francisco, CA 94143 USA
关键词
Allograft; Xenograft; Prosthetics; Efficacy; ACELLULAR DERMAL MATRIX; VENTRAL HERNIA REPAIR; ABDOMINAL-WALL RECONSTRUCTION; COMPROMISED SURGICAL FIELD; INCISIONAL HERNIA; MANAGEMENT; MEDICINE; TISSUE;
D O I
10.1016/j.suc.2013.06.001
中图分类号
R61 [外科手术学];
学科分类号
摘要
After review and evaluation of current clinical data, including significant wound complications, a noteworthy failure rate at 1 year, and high product costs, it is difficult to support the continued use of biologic meshes in incisional hernia repair outside of well-designed and rigorously conducted clinical trials. An industry-sponsored, publicly available registry of biologic prosthetic use for ventral hernia repairs is needed. This straightforward mandate, if properly constructed and implemented, would significantly expand knowledge regarding how these intriguing biomaterials are used and their overall clinical efficacy, thus yielding a more robust basis for the continued use of biologic prosthetics in hernia repair than is currently available.
引用
收藏
页码:1217 / +
页数:10
相关论文
共 50 条
  • [21] LYMPHOGRANULOMA VENEREUM, WHERE DO WE STAND?: CLINICAL RECOMMENDATIONS
    van der Ham, R.
    de Vries, H. J. C.
    DRUGS OF TODAY, 2009, 45 : 39 - 43
  • [22] Where Do We Stand with Immunotherapy for Advanced Pancreatic Ductal Adenocarcinoma: A Synopsis of Clinical Outcomes
    Akhuba, Liia
    Tigai, Zhanna
    Shek, Dmitrii
    BIOMEDICINES, 2022, 10 (12)
  • [23] Epilepsy: Where do we stand? Where are we headed?
    Elger, C. E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 8 - 8
  • [24] ColVI myopathies: where do we stand, where do we go?
    Valérie Allamand
    Laura Briñas
    Pascale Richard
    Tanya Stojkovic
    Susana Quijano-Roy
    Gisèle Bonne
    Skeletal Muscle, 1
  • [25] ColVI myopathies: where do we stand, where do we go?
    Allamand, Valerie
    Brinas, Laura
    Richard, Pascale
    Stojkovic, Tanya
    Quijano-Roy, Susana
    Bonne, Gisele
    SKELETAL MUSCLE, 2011, 1
  • [26] Investigative dermatology: where do we stand and where do we go?
    Maurer, M.
    von Stebut, E.
    EXPERIMENTAL DERMATOLOGY, 2010, 19 (10) : 857 - 857
  • [27] Rye and health - Where do we stand and where do we go?
    Jonsson, Karin
    Andersson, Roger
    Knudsen, Knud Erik Bach
    Hallmans, Goran
    Hanhineva, Kati
    Katina, Kati
    Kolehmainen, Marjukka
    Kyro, Cecilie
    Langton, Maud
    Nordlund, Emilia
    Laerke, Helle Nygaard
    Olsen, Anja
    Poutanen, Kajsa
    Tjonneland, Anne
    Landberg, Rikard
    TRENDS IN FOOD SCIENCE & TECHNOLOGY, 2018, 79 : 78 - 87
  • [28] Scoping Pharmacy Students' Learning Outcomes: Where Do We Stand?
    Pires, Carla
    Cavaco, Afonso
    PHARMACY, 2019, 7 (01)
  • [29] Prediction of treatment outcomes in psychiatry-where do we stand?
    McMahon, Francis J.
    DIALOGUES IN CLINICAL NEUROSCIENCE, 2014, 16 (04) : 455 - 464
  • [30] Where do we stand in the OECD?
    Buske, L
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 1997, 156 (03) : 464 - 464